7 completed, 7 recruiting, 2 not yet recruiting, 1 unknown. 6 Phase 1, 6 Phase 2, 4 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 4, Not yet recruiting 2 |
| Phase 2 | 6 | Completed 3, Recruiting 3 |
| Phase 3 | 4 | Completed 4 |
| Not applicable | 1 | Unknown 1 |
Follow this drug Literature Review of Cyclophosphamide (CTX) trials Research Report on Cyclophosphamide (CTX)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia CD7 CAR-γδT cell（QH106）, Fludarabine (FLU), Cyclophosphamide (CTX) - Leukemia | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 9 | 2025-08-18 | 2025-08-13 |
| QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) Allogeneic TCR-enhanced γδ T cell(QH101), Fludarabine (FLU), Cyclophosphamide (CTX) - MDS, AML | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 9 | 2025-08-15 | 2025-08-20 |
| Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer Prostate cryoablation, Cyclophosphamide (CTX) - Metastatic Prostate Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 104 | 2025-03-01 | 2026-08-28 |
| A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors NK042, Fludarabine (FLU), Cyclophosphamide (CTX) - Advanced Solid Tumors | Phase 1 | Recruiting | Shanghai NK Cell Technology Co., LTD | 76 | 2025-02-07 | 2026-04-06 |
| Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara) - Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory | Phase 2 | Recruiting | University of Illinois at Chicago | 38 | 2025-02-04 | 2026-06-26 |
| Rapid dFLC Response Predict CHR in AL Amyloidosis Dara IV, Bortezomib (drug), Dexamethasone - Systemic AL Amyloidosis | Recruiting | Peking University People's Hospital | 50 | 2024-10-26 | 2026-03-09 | |
| R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Mitoxantrone Hydrochloride Liposome, Rituximab (R), Cyclophosphamide (CTX) - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 108 | 2024-05-30 | 2026-06-10 |
| Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Busulfan (Busulfex), Cyclophosphamide (CTX), Fludarabine (Fludara) - Hematologic Disease | Phase 1 | Recruiting | He Huang | 29 | 2022-08-04 | 2026-06-09 |
| Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation Busulfan (Busulfex), Cyclophosphamide (CTX), Fludarabine (Fludara) - Hematologic Diseases | Phase 1 | Recruiting | He Huang | 29 | 2022-08-04 | 2025-02-05 |
| Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer Lurbinectedin (PM01183), Doxorubicin (DOX), Cyclophosphamide (CTX) - Small-cell Lung Cancer | Phase 3 | Completed | PharmaMar | 613 | 2016-08-30 | 2021-10-28 |
| A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome Mizoribine (MZR), Cyclophosphamide (CTX) - Nephrotic Syndrome | Phase 3 | Completed | Asahi Kasei Therapeutics Corporation | 239 | 2014-11-01 | 2019-01-17 |
| A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis Mizoribine (MZR), Cyclophosphamide (CTX) - Lupus Nephritis | Phase 3 | Completed | Asahi Kasei Therapeutics Corporation | 250 | 2014-11-01 | 2019-06-07 |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, fludarabine phosphate, busulfan - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | University of Wisconsin, Madison | 20 | 2013-05-16 | 2019-11-21 |
| Non-Myeloablative Conditioning and Bone Marrow Transplantation Thymoglobulin, Fludarabine, Cyclophosphamide (CTX) - Sickle Cell Disease, Hemoglobinopathies | Not applicable | Unknown | Vanderbilt-Ingram Cancer Center | 26 | 2013-05-01 | 2024-01-10 |
| Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage Cyclophosphamide (CTX), Vincristine, Doxorubicin - Acute Lymphoblastic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 90 | 2003-06-01 | 2012-02-20 |
| Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia Rituximab, Cyclophosphamide (CTX), Doxorubicin - Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 220 | 2002-11-01 | 2020-12-03 |
| Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer Filgrastim (G-CSF), Carmustine, Cisplatin - Breast Cancer | Phase 3 | Completed | M.D. Anderson Cancer Center | 184 | 1995-09-26 | 2018-11-06 |
Leukemia (3) · Hematologic Diseases (2) · Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Sickle Cell (1) · Breast Neoplasms (1) · Congenital Abnormalities (1) · Hemoglobinopathies (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia, Myeloid, Accelerated Phase (1) · Lupus Nephritis (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Myelodysplastic Syndromes (1) · Nephrotic Syndrome (1)
M.D. Anderson Cancer Center (3) · Anhui Provincial Hospital (2) · Asahi Kasei Therapeutics Corporation (2) · He Huang (2) · Institute of Hematology & Blood Diseases Hospital, China (1) · Peking University People's Hospital (1) · PharmaMar (1) · Shanghai NK Cell Technology Co., LTD (1) · Sun Yat-sen University (1) · University of Illinois at Chicago (1) · University of Wisconsin, Madison (1) · Vanderbilt-Ingram Cancer Center (1)
China (8) · United States (7) · France (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1)
Adetola A Kassim, MD (1) · James Gajewski, MD (1) · Lugui Qiu, Professor (1) · Mark Juckett (1) · Matias Sanchez, MD (1) · Stefan F. Faderl, M.D. (1) · Susan O'Brien, M.D. (1)
PMID 32683127, PMID 36252599, PMID 36990111, PMID 37883803, PMID 38493482, PMID 40085084, PMID 42049986
P30CA014520 (1), P30CA016672 (1)